Approximately one in three women will experience some form of urinary incontinence during their lifetime. Estimates vary ...
3d
Top U.S. Health Official Backed a Medication Policy Shift That Benefited a Company She Has Stock In
Alicia Jackson endorsed a key FDA policy change on hormone replacement therapies while holding at least $115,000 in stock in ...
A systematic review of thirteen qualitative studies identifies five themes in how women, caregivers and healthcare ...
Drugs, Cancer Types, How It Works, and Side Effects / cancer, cancer treatment, carboplatin, chemotherapy drugs, Chemotherapy ...
The VOLGA trial showed that durvalumab plus EV improves EFS, OS, for patients with MIBC who don’t receive cisplatin-based ...
There are patients with muscle-invasive bladder cancer who want to keep their bladder. To what extent did ASTRO support TMT ...
As part of a 12-month trial, eligible women will be able to consult a pharmacist for UTI treatment or the pill with no out-of ...
ASTRO’s first bladder cancer guideline recommends trimodal therapy as a curative option for selected patients and defines ...
About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...
AstraZeneca's Imfinzi combined with Pfizer's Padcev cut the risk of death in muscle-invasive bladder cancer patients by 42%, ...
Radical cystectomy remains a major operation even at experienced centers and with robotic surgical techniques. Data from the ...
The phase 3 VOLGA trial looks at perioperative durvalumab plus enfortumab vedotin, with and without tremelimumab, for muscle-invasive bladder cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results